2021
Randomized Phase II Study of PET Response–Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial
Goodman KA, Ou FS, Hall NC, Bekaii-Saab T, Fruth B, Twohy E, Meyers MO, Boffa DJ, Mitchell K, Frankel WL, Niedzwiecki D, Noonan A, Janjigian YY, Thurmes PJ, Venook AP, Meyerhardt JA, O'Reilly EM, Ilson DH. Randomized Phase II Study of PET Response–Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial. Journal Of Clinical Oncology 2021, 39: 2803-2815. PMID: 34077237, PMCID: PMC8407649, DOI: 10.1200/jco.20.03611.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinChemoradiotherapyCombined Modality TherapyEsophageal NeoplasmsFemaleFluorodeoxyglucose F18FluorouracilFollow-Up StudiesHumansLeucovorinMaleMiddle AgedOxaliplatinPositron-Emission TomographyPrognosisRadiopharmaceuticalsSurvival RateYoung AdultConceptsPositron emission tomographyRepeat positron emission tomographyPET respondersEsophagogastric junction adenocarcinomaStandardized uptake valueInduction FOLFOXPET nonrespondersPCR rateOverall survivalJunction adenocarcinomaPathologic complete response rateRandomized phase II studyBaseline positron emission tomographyMaximum standardized uptake valueInduction chemotherapy regimenComplete response rateEarly response assessmentMedian overall survivalPhase II studyPrimary end pointCombined modality therapySame chemotherapyChemotherapy regimenEligible patientsII study
2020
Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non–Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features
Pathak R, Goldberg SB, Canavan M, Herrin J, Hoag JR, Salazar MC, Papageorge M, Ermer T, Boffa DJ. Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non–Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features. JAMA Oncology 2020, 6: 1741-1750. PMID: 32940636, PMCID: PMC7499246, DOI: 10.1001/jamaoncol.2020.4232.Peer-Reviewed Original ResearchConceptsNode-negative non-small cell lung cancerHigh-risk pathologic featuresNon-small cell lung cancerAdjuvant chemotherapyCell lung cancerPathologic featuresTumor sizeSurvival benefitCohort studyLung cancerNode-negative NSCLCEarly-stage non-small cell lung cancerCox proportional hazards regression modelHigh-risk clinicopathologic featuresProportional hazards regression modelsNational Cancer DatabaseRetrospective cohort studyTreatment-naive patientsAdjuvant chemotherapy useHigh-risk featuresAssociation of survivalHazards regression modelsImmortal time biasChemotherapy useEligible patients